Home >> Health >> Global Glucosamine Market 2016 – Sinochem Qingdao Co. Ltd., Yaizu Suisankagaku Industry Co. Ltd., Sai Gluco Pharma, Wanbury Ltd., Wellable Group Marine Biological & Chemical Co. Ltd., Pacific Rainbow International Inc.

Global Glucosamine Market 2016 – Sinochem Qingdao Co. Ltd., Yaizu Suisankagaku Industry Co. Ltd., Sai Gluco Pharma, Wanbury Ltd., Wellable Group Marine Biological & Chemical Co. Ltd., Pacific Rainbow International Inc.

GlucosamineThis market insight report on Glucosamine analyzes the market by Type and Application at global level and for each of the geographic regions – North America, Europe, China, Asia-Pacific, and Rest of World. The Glucosamine market is segmented by Type into D-Glucosamine and N-Acetyl-Glucosamine; and by Application into Nutraceutical/Pharmaceutical, Feed Additives, and Food Ingredients. Global market by Volume in Metric Tons and Value in US$ is also included. Business profiles of 45 major companies are discussed in the report.

Global Glucosamine market is projected to increase at a CAGR of 17% from 2010 through 2022.

Major Companies profiled in this research report: Sinochem Qingdao Co., Ltd. (China), Yaizu Suisankagaku Industry Co., Ltd. (Japan), Sai Gluco Pharma (India), Wanbury Ltd. (India), Wellable Group Marine Biological & Chemical Co., Ltd. (China), Pacific Rainbow International, Inc. (USA), TSI Health Sciences (USA), Shandong Yibao Biologics Co., Ltd. (China), Stauber Performance Ingredients, Inc. (USA)

Request For Free Report Sample @ http://www.marketresearchstore.com/report/glucosamine-28957#RequestSample

Glucosamine based products were classified as nutraceuticals in most countries worldwide. But now a number of countries (especially Europe) are permitting glucosamine products to be registered as pharmaceuticals. Products sold as drugs need to be approved by national medicines agencies, whereas nutraceuticals in general are governed by much less demanding food regulations. As a result of the US anti-dumping action against shrimp shells from India and the EU ban on seafood imports from China, there was a steep rise in the price of Glucosamine. But since the uplift of the ban price of glucosamine has more or less stabilized. Change in the status of Glucosamine from drug to food has led to the market being opened up.

The disease is caused by mutated prions, and is not similar to other diseases that affect human beings and domestic animals. The main responsibility to control this disease is vested with the pharmaceutical industry and it is influenced in several ways. European Union has imposed very stringent measures for controlling TSE infections in domestic animals. Slaughterhouses in EU are required to test for BSE even the healthy cattle that are 30 years or more of age. From the cattle that die on the farm, those that are 24 months or more of age have to be tested for BSE. Out of the cattle being sent for rendering, those that are 24 months and above of age, are to be tested for presence of BSE infection before rendering. Apart from these, any cattle, which displays any physical symptom of BSE, has to be tested, irrespective of the age thus increasing the market for BSE testing in Europe.

Enquiry About This Report @ http://www.marketresearchstore.com/report/glucosamine-28957#InquiryForBuying

The report serves as a guide to Glucosamine industry covering more than 240 companies that are engaged in Glucosamine R&D, processing, production, and distribution. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, ethical issues, regulatory affairs, and other areas of concern is also covered in the report. Compilation of Worldwide Patents and Research related to Glucosamine is also provided. Estimations and predictions are graphically illustrated by 173 exclusive exhibits for all geographic regions.

About erikjason

Leave a Reply

Your email address will not be published. Required fields are marked *